Year: 2020

Press ReleaseNokia delivers private 5G network to MYNXG for secure IoT solutions development5G connectivity enables MYNXG testing and development of secure end-to-end IoT solutions for high-performance industrial applications Network deployed at MYNXG headquarters in Nuremburg, Germany10 November 2020Espoo, Finland – Nokia has deployed an industrial-grade private wireless 5G campus network at the Nuremburg development center of secure industrial IoT specialist MYNXG.MYNXG will use the Nokia 5G network at its new industrial IoT interoperability test center to develop new secure solutions for the industrial Internet of Things, as well as perform real-life testing of equipment and sensors for a range of OEM and customer projects.MYNXG’s operational technology functions using 5G’s full capability from both a performance and quality of service...

Martin Nes, Chairman of Saga Tankers ASA, has received proxies representing 23 265 588 shares, corresponding to 6.84 % of the company, for the upcomming extraordinary general meeting in Saga Tankers ASA on 10 November 2020.This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, HONG KONG, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER COUNTRY WHERE SUCH PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR RULES OR WOULD REQUIRE ADDITIONAL DOCUMENTS TO BE PREPARED OR REGISTERED OR REQUIRE ANY OTHER ACTIONS TO BE TAKEN, IN ADDITION TO THE REQUIREMENTS UNDER SWEDISH LAW. THIS PRESS RELEASE IS NOT A PROSPECTUS BUT AN ANNOUNCEMENT BY THE BOARD OF DIRECTORS OF KLÖVERN’S CONDITIONAL RESOLUTION TO CONDUCT AN ISSUANCE OF SHARES WITH PREFERENTIAL RIGHTS FOR KLÖVERN’S SHAREHOLDERS. PLEASE SEE IMPORTANT INFORMATION AT THE END OF THIS PRESS RELEASE.On 6 October 2020, the Board of Directors of Klövern AB (publ) (“Klövern” or “the Company”) resolved on a...

EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, I SIN HELHET ELLER I DELAR, DIREKT ELLER INDIREKT I USA, KANADA, JAPAN, AUSTRALIEN, HONGKONG, NYA ZEELAND, SINGAPORE, SYDAFRIKA ELLER NÅGOT ANNAT LAND DÄR SÅDAN PUBLICERING ELLER DISTRIBUTION SKULLE BRYTA MOT TILLÄMPLIGA LAGAR ELLER REGLER ELLER SKULLE KRÄVA ATT YTTERLIGARE DOKUMENTATION UPPRÄTTAS ELLER REGISTRERAS ELLER KRÄVA ATT NÅGON ANNAN ÅTGÄRD VIDTAS, I TILLÄGG TILL DE KRAV SOM STÄLLS ENLIGT SVENSK LAG. DETTA PRESSMEDDELANDE ÄR INTE ETT PROSPEKT UTAN ETT OFFENTLIGGÖRANDE AV STYRELSEN FÖR KLÖVERNS VILLKORADE BESLUT ATT GENOMFÖRA EMISSION AV AKTIER MED FÖRETRÄDESRÄTT FÖR KLÖVERNS AKTIEÄGARE. VÄNLIGEN SE ”VIKTIG INFORMATION” I SLUTET AV DETTA PRESSMEDDELANDE.Den 6 oktober 2020 beslutade styrelsen för Klövern AB (publ) (”Klövern” eller ”Bolaget”) om en fullt garanterad nyemission...

IDEX Biometrics ASA (the “Company”), a leading provider of advanced fingerprint identification and authentications solutions, has successfully conducted a private placement of new shares (the “Private Placement”).The gross proceeds of the Private Placement amounts to NOK 70 million by issue of 42.5 million new shares at NOK 1.65 per share. The Private Placement took place 9 November 2020 after close of Oslo Børs.The additional funds are expected to meet the Company’s capital requirements in the medium term.The net proceeds from the Private Placement will be used to fund growth opportunities and for general corporate purposes.Vince Graziani, CEO, IDEX Biometrics, said: “This additional capital will enable IDEX to deliver on our commitments to current customers and new customers when we are moving to large scale commercialization....

Montrouge, France, November 10, 2020DBV Technologies to Highlight Data on Viaskin™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020Meeting also will feature virtual industry symposium on managing food allergies amid the COVID-19 pandemicDBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new analyses of clinical studies investigating epicutaneous immunotherapy to treat peanut allergy with a patch (DBV712 250 µg) will be presented at the virtual American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, Nov. 13-15, 2020. Four abstracts have been accepted, including one oral presentation and three poster presentations. DBV will also host a virtual booth in the ACAAI virtual exhibit hall.The data to...

Montrouge, France, le 10 novembre (7h30 CET) 2020DBV Technologies va présenter des données sur le mode d’administration du traitement Viaskin® Peanut et l’expérience des patients au congrès annuel de l’ACAAI 2020La conférence comprendra également un symposium virtuel de l’industrie sur la gestion des allergies alimentaires dans le contexte de la pandémie COVID-19DBV Technologies (Euronext: DBV – ISIN : FR0010417345 – Nasdaq Stock Market: DBVT), une société biopharmaceutique au stade clinique, a annoncé aujourd’hui que de nouvelles analyses d’études cliniques portant sur l’immunothérapie épicutanée pour traiter l’allergie aux arachides à l’aide d’un patch (DBV712 250 µg) seront présentées lors de la réunion scientifique annuelle virtuelle de l’American College of Allergy, Asthma & Immunology...

 AttachmentEN_NCX470 Denali Phase 3 Start PR_20201110_F

 Pièce jointeFR_NCX 470 Denali Phase 3 Start PR_20201110_F